PRMT5 is overexpressed in breast cancer patients, and it results in the activation of the Wnt/beta-catenin proliferative signaling pathway, leading to enhanced expression of c-myc and CYCLIN D1 and SURVIVIN. This evidence concerns the gene PRMT5 and breast carcinoma.